Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Precede Biosciences has announced positive results for its novel liquid biopsy assay, which can classify human epidermal growth factor receptor 2 (HER2) status in multiple cancers and predict ...

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede ...

Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...

Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab ...

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue ...

Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as ...

Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers ...

NEW CITY, N.Y., December 8, 2023 (Newswire.com) - The Pancreatic Cancer Early Detection (PRECEDE) Consortium, a beacon of hope in the global fight against pancreatic cancer, hosted its fifth annual ...